Angiotensin II receptor blockersAngiotensin II receptor blockers (ARBs) are used to treat conditions such as high blood pressure and heart failure. Find out more about this class of medication.
By Mayo Clinic Staff
Angiotensin II receptor blockers help relax your blood vessels, which lowers your blood pressure and makes it easier for your heart to pump blood.
Angiotensin II is a natural substance in your body that affects your cardiovascular system in many ways, such as by narrowing your blood vessels. This narrowing can increase your blood pressure and force your heart to work harder. Angiotensin II also starts the release of a hormone that increases the amount of sodium and water in your body, which can lead to increased blood pressure. Angiotensin II can also thicken and stiffen the walls of your blood vessels and heart.
Angiotensin II receptor blockers block the action of angiotensin II. That allows blood vessels to widen (dilate).
Examples of angiotensin II receptor blockers
Several angiotensin II receptor blockers are available. Which one is best for you depends on your health and the condition being treated.
Examples of angiotensin II receptor blockers include:
Feb. 01, 2014
- Azilsartan (Edarbi)
- Candesartan (Atacand)
- Eprosartan (Teveten)
- Irbesartan (Avapro)
- Losartan (Cozaar)
- Olmesartan (Benicar)
- Telmisartan (Micardis)
- Valsartan (Diovan)
See more In-depth
- Kaplan NM, et al. Kaplan's Clinical Hypertension. 10th ed. Philadelphia, Pa.: Wolters Kluwer Health Lippincott Williams & Wilkins; 2010:192.
- Types of blood pressure medications. American Heart Association. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/PreventionTreatmentofHighBloodPressure/Types-of-Blood-Pressure-Medications_UCM_303247_Article.jsp. Accessed April 17, 2013.
- Taylor AA, et al. Angiotensin receptor blockers: Pharmacology, efficacy, and safety. The Journal of Clinical Hypertension. 2011;13:677.
- Mann JFE. Choice of therapy in primary (essential) hypertension: Recommendations. http://www.uptodate.com/home. Accessed April 17, 2013.
- Chobanian AV, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. New England Journal of Medicine. 2003;289:2560.
- Olmesartan medoxomil: Drug safety communication. U.S. Food and Drug Administration. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm359528.htm. Accessed July 22, 2013.